Trials / Completed
CompletedNCT01723878
ASPET Study: An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced Non-Small Cell Lung Cancer Harbouring EGFR Activating Mutations
Observational, Post-authorization, Prospective Study for Evaluating Patterns of Disease Progression in Patients With Advanced Non-small-cell Lung Carcinoma (NSCLC) Harbouring EGFR Activating Mutations Treated With Erlotinib in First Line.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 144 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This observational study will evaluate the patterns of disease progression in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harbouring EGFR activating mutations receiving Tarceva (erlotinib) as first-line treatment. Patients will be followed for up to 12 months after progression of disease.
Conditions
Timeline
- Start date
- 2013-12-30
- Primary completion
- 2017-06-20
- Completion
- 2017-06-20
- First posted
- 2012-11-08
- Last updated
- 2017-09-11
Locations
43 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT01723878. Inclusion in this directory is not an endorsement.